IP Library Granted Patent US 8,491,925
Granted Patent B2
US 8,491,925 · App. 13/310,326 · Granted Jul 23, 2013

Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,491,925
App. No.
13/310,326
Granted
Jul 23, 2013
Kind
B2
Abstract

A method and device for local delivery of a water-insoluble therapeutic agent to the tissue of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with a non-durable coating which comprises poly(HEMA) complexed with iodine and has a substantially water-insoluble therapeutic agent dispersed therein. The medical disposable device is inserted into a body lumen, and expanded to contact the non-durable coating against the body lumen and deliver the substantially water-insoluble therapeutic agent to the body lumen tissue.

Claims (24)

1. A method of coating a catheter balloon comprising:

coating a catheter balloon with a coating solution comprising poly(HEMA), iodine, an organic solvent, and a substantially water-insoluble therapeutic agent; and

drying the catheter balloon to form a water soluble coating on the catheter balloon, wherein the poly(HEMA) is complexed with the iodine in the water soluble coating.

2. The method of claim 1 , wherein coating the catheter balloon with a coating solution comprises dip coating the catheter balloon in the coating solution.

3. The method of claim 1 , wherein the substantially water-insoluble therapeutic agent is selected from the group consisting of an anti-proliferative agent, anti-platelet agent, anti-inflammatory agent, anti-thrombotic agent, and thrombolytic agent.

4. The method of claim 3 , wherein the substantially water-insoluble therapeutic agent is paclitaxel.

5. The method of claim 1 , wherein the poly(HEMA) is prepared by atom transfer radical polymerization (ATRP) using a morpholine based initiator (ME-Br).

6. The method of claim 1 , wherein the poly(HEMA) has a Mn below 8 KD.

7. The method of claim 6 , wherein the poly(HEMA) has a Mn of approximately 7 KD.

8. The method of claim 1 , wherein the organic solvent is 2-propanol.

9. The method of claim 1 , wherein the coating solution comprises acetone.

10. The method of claim 1 , wherein the coating solution comprises propylene glycol.

11. A method of coating a catheter balloon comprising:

coating a catheter balloon with a coating solution comprising poly(HEMA), iodine, an organic solvent, and a substantially water-insoluble therapeutic agent; and

drying the catheter balloon to form a water soluble coating on the catheter balloon, wherein the iodine is non-covalently bound in the water soluble coating.

12. The method of claim 11 , wherein coating the catheter balloon with a coating solution comprises dip coating the catheter balloon in the coating solution.

13. The method of claim 11 , wherein the substantially water-insoluble therapeutic agent is selected from the group consisting of an anti-proliferative agent, anti-platelet agent, anti-inflammatory agent, anti-thrombotic agent, and thrombolytic agent.

14. The method of claim 11 , wherein the substantially water-insoluble therapeutic agent is paclitaxel.

15. The method of claim 11 , wherein the poly(HEMA) is prepared by atom transfer radical polymerization (ATRP) using a morpholine based initiator (ME-Br).

16. The method of claim 11 , wherein the poly(HEMA) has a Mn below 8 KD.

17. The method of claim 16 , wherein the poly(HEMA) has a Mn of approximately 7 KD.

18. The method of claim 11 , wherein the organic solvent is 2-propanol.

19. The method of claim 11 , wherein the coating solution comprises acetone.

20. The method of claim 11 , wherein the coating solution comprises propylene glycol.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0142 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0066 →
SECURITY INTEREST (REVOLVER) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0425 →
SECURITY INTEREST (TERM) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0506 →
RELEASE OF SECURITY INTEREST Recorded Dec 11, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: THE SPECTRANETICS CORPORATION
Reel/Frame 037268/0793 →
SECURITY INTEREST Recorded Jul 2, 2015
From: THE SPECTRANETICS CORPORATION
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 036055/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2015
From: COVIDIEN LP
To: THE SPECTRANETICS CORPORATION
Reel/Frame 035074/0106 →
MERGER Recorded Aug 9, 2013
From: CV INGENUITY LLC
To: COVIDIEN LP
Reel/Frame 030974/0870 →
CHANGE OF NAME Recorded Aug 9, 2013
From: CV INGENUITY CORP.
To: CV INGENUITY LLC
Reel/Frame 030994/0255 →